Does Treatment of Acute Herpes Zoster Prevent or Shorten Postherpetic Neuralgia? A Systematic Review of the Literature

,

Original Research

Does Treatment of Acute Herpes Zoster Prevent or Shorten Postherpetic Neuralgia? A Systematic Review of the Literature

J Fam Pract. 2000 March;49(3):255-264

By

Brian S. Alper, MD

References

REFERENCE

1. Helgason S, Sigurdsson JA, Gudmundsson S. The clinical course of herpes zoster: a prospective study in primary care. Eur J Gen Pract 1996;2:12-6.

2. Burgoon CF, Burgoon JS, Baldridge GD. The natural history of herpes zoster. JAMA 1957;164:265-9.

3. Volmink J, Lancaster T, Gray S, Silagy C. Treatments for postherpetic neuralgia—a systematic review of randomized controlled trials. Fam Pract 1996;13:84-91.

4. Lancaster T, Silagy C, Gray S. Primary care mangement of acute herpes zoster: systematic review of evidence from randomized controlled trials. Br J Gen Pract 1995;45:39-45.

5. Schmader KE, Studenski S. Are current therapies useful for the prevention of postherpetic neuralgia? A critical analysis of the literature. J Gen Intern Med 1989;4:83-9.

6. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:89-96.

7. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valacyclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39:1546-53.

8. Bowsher D. The effects of preemptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997;13:327-31.

9. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837-42.

10. Lycka BAS. Postherpetic neuralgia and systemic corticosteroid therapy: efficacy and safety. Int J Dermatol 1990;29:523-7.

11. Post BT, Philbrick JT. Do corticosteroids prevent postherpetic neuralgia? A review of the evidence. J AM Acad Dermatol 1988;18:605-10.

12. Dwyer DE. Management issues in herpes zoster. Aust Fam Physician 1996;25:299-307.

13. Wood MJ. How should we measure pain in herpes zoster? Neurology 1995;45(suppl):S61-2.

14. Emerson JD, Burdick E, Hoaglin DC, Mosteller F, Chalmers TC. An empirical study of the possible relation of treatment differences to quality scores in controlled randomized clinical trials. Control Clin Trials 1990;11:339-52.

15. Mulrow CD, Oxman, AD, eds. “Quality” scales and checklists. Cochrane Collaboration handbook, section 6.7.2. In: The Cochrane library. The Cochrane Collaboration. Oxford, England: Update Software; 1997, issue 4.

16. Wood MJ, Ogan PH, McKendrick MW, Care CD, McGill JI, Webb EM. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988;85:79-83.

17. Cobo LM, Foulks GN, Liesegang T, et al. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology 1986;93:763-70.

18. McKendrick MW, McGill JI, Wood MJ. Lack of effect of acyclovir on postherpetic neuralgia. BMJ 1989;298:431.-

19. McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. BMJ 1986;293:1529-32.

20. Wood MJ, McKendrick MW, McGill JI. Oral acyclovir for acute herpes zoster infections in immune-competent adults. Infection 1987;15(suppl):S9-13.

21. McGill JI, White JE. Acyclovir and post-herpetic neuralgia and ocular involvement. BMJ 1994;309:1124.-

22. McKendrick MW, Wood MJ. Acyclovir and post-herpetic neuralgia two other participating study centres report different results. BMJ 1995;310:1005.-

23. Crooks RJ, Jones DA, Fiddian AP. Zoster-associated chronic pain: an overview of clinical trials with acyclovir. Scand J Infect Dis 1991;78(suppl):62-8.

24. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996;22:341-7.

25. Huff JC, Bean B, Balfour HH, et al. Therapy of herpes zoster with oral acyclovir. Am J Med 1988;85:84-9.

26. Huff JC. Oral acyclovir therapy of acute herpes zoster: a mutlicentre study. Res Clin Forums 1987;9:37-45.

27. Huff JC, Drucker JL, Clemmer A, Laskin OL, Connor JD, Bryson YJ, et al. Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol 1993;Suppl 1:93-6.

28. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989;102:93-5.

29. Harding SP, Porter SM. Oral acyclovir in herpes zoster ophthalmicus. Curr Eye Res 1991;10(suppl):177-82.

30. Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia: a meta-analysis. Arch Intern Med 1997;157:909-12.

31. Whitley RJ, Weiss H, Gnann JW, et al. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. Ann Intern Med 1996;125:376-83.

32. The Cochrane Collaboration. The database of abstracts of reviews of effectiveness. DARE-978103. In: The Cochrane library. Oxford, England: Update Software; 1998, issue 4.

33. Hoang-Xuan T, Buchi EB, Herbort CP, et al. Oral acyclovir for herpes zoster ophthalmicus. Ophthalmology 1992;99:1062-71.

34. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994;330:896-900.

35. Wassilew SW, Reimlinger S, Nasemann T, Jones D. Oral acyclovir for herpes zoster: a double-blind controlled trial in normal subjects. Br J Dermatol 1987;117:495-501.

36. McKendrick MW, Care C, Burke C, Hickmott E, McKendrick GDW. Oral acyclovir in herpes zoster. J Antimicrob Chemother 1984;14:661-5.

37. Dworkin RH, Boon RJ, Griffin DRG, Phung D. Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. J Infect Dis 1998;178(suppl):S76-80.

38. Watson CP, Deck JH, Morshead C, Van der Koody D, Evans RJ. Post-herpetic neuralgia: further post-mortem studies of cases with and without pain. Pain 1991;44:105-17.

39. Esmann V, Kroon S, Peterslund NA, et al. Prednisolone does not prevent post-herpetic neuralgia. Lancet 1987;2:126-9.

40. Clemmensen OJ, Andersen KE. ACTH versus prednisone and placebo in herpes zoster treatment. Clin Exp Dermatol 1984;9:557-63.

41. Keczkes K, Basheer AM. Do corticosteroids prevent post-her-petic neuralgia? Br J Dermatol 1980;102:551-5.

42. Eaglstein WH, Katz R, Brown JA. The effects of early corticosteroid therapy on the skin eruption and pain of herpes zoster. JAMA 1970;211:1681-3.

43. Herbert DA, Carson MP. Acyclovir plus steroids for herpes zoster. Ann Intern Med 1997;126:831-2.

44. MacFarlane LL, Simmons MM, Hunter MH. The use of corticosteroids in the management of herpes zoster. J Am Board Fam Pract 1998;11:224-8.

45. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37:589-96.

46. Ahmed HE, Craig WF, White PF, et al. Percutaneous electrical nerve stimulation: an alternative to antiviral drugs for acute herpes zoster. Anesth Analg 1998;87:911-4.

47. Wood MJ, Balfour H, Beutner K, et al. How should zoster trials be conducted? J Antimicrob Chemother 1995;36:1089-101.

48. Dworkin RH, Portenoy RK. Proposed classification of herpes zoster pain. Lancet 1994;343:1648.-

49. Van den Broek PJ, Stuyt PM, van der Meer JW. Acyclovir for herpes zoster. N Engl J Med 1994;331:481.-

50. Gershon A. Varicella: to vaccinate or not to vaccinate? Arch Dis in Childhood 1998;79:470-1.

51. Oxman MN. Immunization to reduce the frequency and serverity of herpes zoster and its complications. Neurology 1995;45(suppl):S41-6.

52. Stephenson J. Shingles vaccine trial in health agencies update. JAMA 1999;282:625.-Available on the World Wide Web at http://jama.ama-assn.org/issues/v282p7/full/jha90006-4.html.

53. Garnett GP, Grenfell BT. The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster. Epidemiol Infect 1992;108:513-28.

OBJECTIVE: Our goal was to determine if any treatment of acute herpes zoster alters the incidence or duration of postherpetic neuralgia (PHN), a common sequela in elderly patients.

SEARCH STRATEGY: We systematically searched MEDLINE and The Cochrane Library. We also examined the reference lists of identified trials and reviews.

SELECTION CRITERIA: We included all randomized controlled trials of treatments of zoster published in English that included assessment of pain at any time after rash healing.

DATA COLLECTION/ANALYSIS: Forty-two trials met inclusion criteria, and 2 reviewers independently evaluated them for methodologic quality and the statistical and clinical significance of results.

MAIN RESULTS: Four placebo-controlled trials of oral acyclovir with 692 patients provided marginal evidence for reduction in pain incidence at 1 to 3 months following zoster onset. Famciclovir significantly reduced duration but not incidence of PHN in one placebo-controlled trial of 419 patients. Valacyclovir significantly reduced duration but not incidence of PHN in one acyclovir-controlled trial of 1141 patients. Steroids had no effect on PHN. Amitriptyline for 90 days reduced pain incidence at 6 months in one placebo-controlled trial of 80 patients. A single trial of percutaneous electrical nerve stimulation (PENS) in 50 patients suggested a decrease in pain incidence at 3 and 6 months compared with famciclovir.

CONCLUSIONS: There is limited evidence that current interventions prevent or shorten PHN. Famciclovir and valacyclovir have been shown to reduce the duration of PHN in single published trials. Well-designed and larger trials of amitriptyline and PENS should be conducted.

Clinical question

What can be done at the time of acute herpes zoster treatment toprevent or reduce postherpetic neuralgia?

Postherpetic neuralgia (PHN) is the most common complication of zoster and is much more prevalent among older patients.^1,2 The results of the largest English-language prospective study of patients presenting with zoster,¹ involving 457 patients from 62 general practitioners in Iceland, suggest that the average family physician caring for 2000 patients would expect to see 4 cases of zoster per year and one case of PHN lasting more than 3 months once in 3 years. Among patients older than 60 years in this study, 19% had pain at 3 months, and 8% had pain at 12 months. Among the 183 patients younger than 40 years, only one had pain at 3 months. The authors of the second largest prospective study of zoster,² involving 206 patients from multiple specialty services in Philadelphia, Pennsylvania, found that 14% of patients older than 50 years had pain at 3 months, and 7% had pain at 6 months. In this study, no patients younger than 50 years had pain at 3 months. In comparison, randomized controlled trials of zoster treatment have reported ranges of 16.7% to 60% of patients receiving placebo having pain at 3 months and 5% to 39.1% having pain at 6 months.

Several systematic reviews have addressed treatment or prevention of PHN.^3-5 New trial data^6-9 and discrepancies in the literature^4,10,11 prompted our paper. Differences in the definition of PHN complicated our review of the medical literature.^12,13 For this review, PHN is defined as any pain after cutaneous healing of zoster, and zoster-associated pain (ZAP) is defined as any pain associated with zoster (acute zoster pain and PHN). This review is limited to randomized controlled trials performed at the time of zoster with follow-up addressing the incidence or duration of PHN or ZAP.

Methods

MEDLINE (1966 to present) was searched on December 29, 1998, using PubMed and combining the terms “zoster” or “post-herpetic neuralgia” or “postherpetic neuralgia” or “post-herpetic pain” or “postherpetic pain,” and publication type “clinical trial” (including phases I-IV) or “controlled clinical trial” or “randomized controlled trial.” We searched The Cochrane Controlled Trials Register 1998, issue 4, using the same terms. We also identified trials through article reference lists and Web-based searches. One author conducted independent searches and was unable to identify any additional randomized controlled trials.

For our review we included randomized controlled trials published in English that enrolled primarily immunocompetent subjects with acute herpes zoster and addressed relevant end points (incidence of pain at any time after rash healing in zoster patients or duration of ZAP or PHN). The two authors independently evaluated the trials meeting these inclusion criteria for quality of randomization, allocation concealment, blinding, baseline difference assessment, methods of data collection, adequacy of follow-up (duration and methods), accounting for dropouts, and intention-to-treat analysis. We rated methodologic quality as good, fair, or poor on the basis of an overall assessment of these features. We did not use explicit validity checklists with summary scores, because they have not been shown to predict the effect of bias on treatment differences (ie, they have not been shown to provide more reliable assessments of validity).^14,15 Discordant ratings of trial quality were resolved through the consensus of both investigators.